 | | Vol. 6.03 – 25 January, 2021 |
| |
|
|
| Scientists demonstrated that mast cell-derived tumor necrosis factor was crucial for neutrophil extravasation to sites of contact hypersensitivity-induced skin inflammation by promoting intraluminal crawling.
[Immunity] |
|
 |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| By means of high-throughput screening of the combinatorial space of mechanical-strain level and of the presence of particular kinase inhibitors, investigators showed that human mesenchymal stem cells could be mechanically and pharmacologically conditioned to enhance vascular regeneration in vivo.
[Nature Biomedical Engineering] |
|
|
|
| A co-culture of human vascular endothelial cells with pericytes was developed that mimicked the blood–brain barrier. This dual channel microfluidics system enabled 3D localization microscopy of the cytoskeleton and 3D single-molecule-sensitive tracing of lipoprotein particles.
[ACS Nano] |
|
|
|
| Open chromatin landscape profiling combined with genome-wide transcriptome analysis showed robust transcriptional upregulation of liver sinusoidal endothelial cells-vascular cell adhesion molecule 1 in murine nonalcoholic steatohepatitis.
[Journal of Clinical Investigation] |
|
|
|
| In cell experiments, network formation of human umbilical vein endothelial cells (HUVECs) within fibrinogen‐based hydrogels with different concentrations of hyaluronic acid were systematically studied.
[Small] |
|
|
|
| Investigators measured oscillatory shear and pulsatile shear transcriptomic responses in human aortic endothelial cells (HAECs) over 24 hours and compared these temporal responses of HAECs with our previous findings on HUVECs.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Lentivirus-mediated overexpression, as well as antisense oligonucleotide-based silencing, modulated H19 in vitro. In vivo analyses used constitutive H19 knockout mice.
[Journal of the American Society of Nephrology] |
|
|
|
| The authors identified miR-130a as a mediator of the hypoxic response in human primary endothelial colony forming cells, a well-characterized subtype of endothelial progenitor.
[Molecular Therapy-Nucleic Acids] |
|
|
|
| Scientists found that Toll-like receptor 2 (TLR2) was highly abundant in the endothelium within various tissues using TLR2-IRES-EGFP reporter mice and was required for proinflammatory endothelial cell function.
[Science Signaling] |
|
|
|
| The authors identified miR-130a as a mediator of the hypoxic response in human primary endothelial colony forming cells, a well-characterized subtype of endothelial progenitor.
[Molecular Therapy-Nucleic Acids] |
|
|
|
| Investigators probed the potential of bone marrow stem cells engineered with chemically modified mRNAs encoding the hBMP-2 and VEGF-A gene to therapeutically heal bone.
[Communications Biology] |
|
|
|
| Epithelial, dermal papilla, and vascular endothelial cells initially formed a single aggregate, which subsequently became a dumbbell-shaped hair follicle germs, wherein the vascular endothelial cells localized in the region of dermal papilla cells.
[Scientific Reports] |
|
|
|
| Investigators tested whether fenofibrate, with its anti-inflammatory and vasoprotective effects, could improve myocardial function by activating endothelial progenitor cells through the eNOS pathway in a doxorubicin-induced cardiomyopathy mouse model.
[Scientific Reports] |
|  |
|
|
|
| Recent bioengineering approaches allow for the generation of 3D microvessels and organ-specific vasculature that provide precise control of vessel architecture and flow dynamics, and hold great promise for malaria research.
[Trends in Parasitology] |
|
|
|
|
| Roche announced positive topline results from two identically designed global phase III studies, TENAYA and LUCERNE, evaluating its investigational bispecific antibody, faricimab, in people living with neovascular or “wet” age-related macular degeneration.
[F. Hoffmann-La Roche Ltd] |
|
|
|
| Caladrius Biosciences, Inc. announced that it has treated the first patient in its Phase IIb FREEDOM trial of CLBS16 as a therapy for coronary microvascular dysfunction at The Christ Hospital Health Network in Cincinnati, Ohio.
[Caladrius Biosciences, Inc.] |
|
|
|
|
|
|
|
| | University of Birmingham – Birmingham, England, United Kingdom |
|
|
|
| | University of California San Francisco – San Francisco, California, United States |
|
|
|
| | University Medical Center Groningen – Groningen, Netherlands |
|
|
|
| | Oklahoma Medical Research Foundation – Oklahoma City, Oklahoma, United States |
|
|
|
| | University of Buffalo – Buffalo, New York, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
